



# ▶ Save The Date ◀





Speaker




**Dr Mary Ann Anderson**

*MBBS, FRACP, FRCPA, PhD  
Hematologist, The Royal Melbourne Hospital and  
Peter MacCallum Cancer Centre  
Clinician Researcher, The Walter and Eliza Hall Institute*

Doctor Anderson is a hematologist at the Royal Melbourne Hospital and Peter MacCallum Cancer Centre specializing in high and low grade lymphomas with a particular interest in early phase clinical trial development. She holds a joint position at the Walter and Eliza Hall Institute as a post-doctoral clinician scientist.

Doctor Anderson's research since 2011 has focused on the development of targeted therapy for the treatment of B cell malignancies. As part of this, she has been involved in the development of venetoclax, the first targeted BCL2 inhibitor, for the use in B cell malignancies. Her work is now focused on identifying biomarkers for venetoclax efficacy, as well as understanding mechanisms for the development of resistance to the agent and identifying rational drug combinations for clinical trial testing.

 ***The complete agenda and more details will follow soon.***  
***For RSVP or more information, please contact Joleen Tay +6010-221 9233***

Full prescribing information is available upon request.  
For Medical/Healthcare Professionals only.

**ABBVIE SDN BHD** (987315-T)

Level 9 Menara Lien Hoe, No. 8 Persiaran Tropicana,  
47410 Petaling Jaya, Selangor, Malaysia.

TEL +603-7883 6888 FAX +603-7883 6838 [www.abbvie.com](http://www.abbvie.com)